These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28201726)

  • 21. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
    Trinh NH; Hoblyn J; Mohanty S; Yaffe K
    JAMA; 2003 Jan; 289(2):210-6. PubMed ID: 12517232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
    Li Y; Hai S; Zhou Y; Dong BR
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of memantine for the treatment of Alzheimer's disease.
    Matsunaga S; Kishi T; Nomura I; Sakuma K; Okuya M; Ikuta T; Iwata N
    Expert Opin Drug Saf; 2018 Oct; 17(10):1053-1061. PubMed ID: 30222469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metrifonate for Alzheimer's disease.
    López-Arrieta JM; Schneider L
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donepezil for mild and moderate Alzheimer's disease.
    Birks JS; Melzer D; Beppu H
    Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey R
    Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
    Johannsen P
    CNS Drugs; 2004; 18(12):757-68. PubMed ID: 15377166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
    Burns A; O'Brien J; ; Auriacombe S; Ballard C; Broich K; Bullock R; Feldman H; Ford G; Knapp M; McCaddon A; Iliffe S; Jacova C; Jones R; Lennon S; McKeith I; Orgogozo JM; Purandare N; Richardson M; Ritchie C; Thomas A; Warner J; Wilcock G; Wilkinson D;
    J Psychopharmacol; 2006 Nov; 20(6):732-55. PubMed ID: 17060346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic treatments of dementia.
    Bonner LT; Peskind ER
    Med Clin North Am; 2002 May; 86(3):657-74. PubMed ID: 12171061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physostigmine for Alzheimer's disease.
    Coelho F; Birks J
    Cochrane Database Syst Rev; 2001; 2001(2):CD001499. PubMed ID: 11405996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.